Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19952
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLiew, David F L-
dc.contributor.authorLeung, Jessica L Y-
dc.contributor.authorLiu, Bonnia-
dc.contributor.authorCebon, Jonathan S-
dc.contributor.authorFrauman, Albert G-
dc.contributor.authorBuchanan, Russell R C-
dc.date2018-
dc.date.accessioned2018-12-17T00:55:59Z-
dc.date.available2018-12-17T00:55:59Z-
dc.date.issued2018-11-22-
dc.identifier.citationInternational journal of rheumatic diseases 2018; online first: 22 November-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19952-
dc.description.abstractTo investigate whether any patient or treatment characteristics are associated with the development of rheumatic immune-related adverse events (irAEs) following programmed cell death protein 1 (PD-1) inhibitor therapy for cancer. This was a retrospective chart review of all patients who were dispensed nivolumab or pembrolizumab at a single center before 1 January, 2017, with follow-up until 1 July, 2017. Patients with any diagnosis of a non-cutaneous irAE were identified, regardless of severity, and rheumatic irAEs were characterized. Of 244 episodes of therapy, a non-cutaneous irAE occurred in 72 (29.5%). Rheumatic irAEs were diagnosed in 19 episodes of therapy (7.8%), with 12 de novo diagnoses (5.1% of episodes without a pre-existing autoimmune rheumatic disease) and 7 exacerbations of existing disease. Review by a rheumatologist occurred in only 11 of these. Rheumatic irAEs were more common in patients with a good oncological response to therapy (relative risk [RR] 11.16), those being treated for melanoma (RR 2.94) and those who developed another non-cutaneous irAE (RR 2.64). Rheumatic irAEs are relatively common with PD-1 inhibitor therapy, and appear to be associated with a good oncological response to therapy. Many rheumatic irAEs were not referred to rheumatological services. Prospective systematic investigation would be of benefit to explore these characteristics.-
dc.language.isoeng-
dc.subjectantineoplastic agents-
dc.subjectarthritis-
dc.subjectdrug-related side effects and adverse reactions-
dc.subjectimmunological-
dc.subjectprogrammed cell death 1 receptor-
dc.titleAssociation of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.-
dc.typeJournal Articleen
dc.identifier.journaltitleInternational journal of rheumatic diseases-
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationDepartment of Rheumatology, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1111/1756-185X.13444-
dc.type.contentTexten
dc.identifier.orcid0000-0001-8451-8883-
dc.identifier.orcid0000-0002-3898-950X-
dc.identifier.pubmedid30549256-
dc.type.austinJournal Article-
local.name.researcherBuchanan, Russell R C
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptRheumatology-
crisitem.author.deptClinical Pharmacology and Therapeutics-
crisitem.author.deptRheumatology-
crisitem.author.deptRheumatology-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptClinical Pharmacology and Therapeutics-
crisitem.author.deptRheumatology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

34
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.